The human leukocyte antigen (HLA) system in human is the major histocompatibility complex (MHC). It is responsible for the major immune response triggered by transplantation antigens. These antigens have been well characterized using allo-antibodies against leukocytes. The primary biological role of HLA molecules is in the regulation of immune response. Graft rejection has been found to be associated with the development of antibodies against HLA. 1 The HLA testing in solid organ transplantation was started by Paul Terasaki in 1960s by serologic methods using complement-dependent cell-mediated cytotoxicity technique. 2 The HLA mismatch between donor and recipient provides an estimate of the immunologic risk of a transplant recipient in the context of his donor. Transplant laboratories have important role to play for estimation of the rejection risk as a part of lab and clinical evaluation. Molecular HLA typing methods characterize and identify HLA alleles more accurately. This helps in more specific HLA antibody detection with improved sensitivity and specificity than serologic methods. Sensitive and specific analysis of HLA antibodies is necessary to identify the risks faced by sensitized recipients and also to explore novel approaches for successfully transplanting these patients by desensitization, acceptable matching, and paired kidney exchange (donor swap). Repeated pre-transplant antibody screening by HLA laboratories is very important for solid organ transplant immunological evaluation. The recipient immune system will recognize the allograft as foreign and initiate inflammatory events resulting in allograft damage. The pre-transplant donor-specific antibody (DSA) development is an important predictor of posttransplant acute and chronic antibody responses resulting in allograft failure. 3, 4 HLA typing: HLA class I molecules (A, B, and Cw) are found on the surface of all nucleated cells in the body. HLA class II (DR, DP, and DQ) molecule's expression is limited to B-cells, antigen-presenting cells (APC), and activated microvascular endothelial cells. A major initiator of the alloimmune response in solid organ transplantation is recognition of nonself HLA by recipient T-cells. Serologic HLA typing: It requires various HLA specificities of wide range of sera containing well-characterized anti-HLA antibodies. It is used in commercially prepared trays which contain sera with antibodies to all common, and many of the rare HLA alleles. Patient lymphocytes are mixed with the various sera in the tray wells and incubated with complement and a vital dye. If the cell has antigens on its surface to which antibody in a particular well are able to bind, then complement is activated in those wells, the membrane attack complex forms and inserts into the cell membrane, cell death occurs, and the vital dye (often eosin) is taken up into the cell. Cell death should therefore occur in any well in which the cell surface antigen and serum antibody are matched, and those wells are then identified under inverted phase contrast microscope. Comparing and eliminating the serologic specificities of the positive wells help assign the HLA phenotype. Molecular typing: HLA molecules are proteins encoded by DNA regions on the short arm of chromosome 6. With their sequences well described, HLA typing is becoming increasingly performed using following molecular methods: (1) Sequencespecific primer (SSP), (2) Sequence-specific oligonucleotide probes (SSOP), and (3) DNA sequencing. SSP: DNA is isolated from the whole blood and amplified in multiple wells, each containing specific primers complementary to particular HLA alleles. If the DNA is complementary to the alleles in a given well, then an amplification product would be formed. The contents of the wells are then run on gel electrophoresis (agarose gel) system. If amplified product is present, then a band will be detected, and the HLA typing is assigned by the primers that were placed in that particular well. The composition of the primers in each well permits positive identification of the HLA characteristics. SSOP: Oligonucleotide probes that are complementary to the unique segments of the DNA of different alleles are mixed with amplified DNA. Unique fluorescent tags distinguish those probes that are complimentary to the DNA so that the HLA allele is identified. DNA sequencing: Sequencing determines the exact order of nucleotides in the gene of interest, and the HLA type is assigned by correlation and in reference to the published HLA allele sequences in (Immuno-Gene-Tics project) IMGT database.
i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 8 3 -8 5 CDC cross-match is important as it helps in validating recipient-donor compatibility and predicting risk of antibodymediated rejection (ABMR). Pre-transplantation anti-HLA screening and cross-matching is necessary to avoid graft dysfunction after transplantation because generation of pretransplant or de novo anti-allograft antibodies may result in graft dysfunction and ABMR.
Flow cytometry and cross-matching: Recipient serum is incubated with donor lymphocytes, which are then stained with a fluorochrome-conjugated anti-IgG antibody that remains bound only if DSA is initially bound to the cell surface. Additional antibodies with different fluorochromes that are specific to unique B and T lymphocyte surface proteins can be added such that when one runs through a flow cytometer, and the B and T cells may be easily distinguished and individually interrogated for the fluorochrome identifying any DSA. The output of the flow crossmatch is semiquantitative (number of channel shifts of mean fluorescence above the baseline or standardized against molecules of equivalent soluble fluorescence beads), although quantification measures and thresholds for positivity can vary between individual laboratories.
Luminex-based solid phase assays: In these tests, microbeads coated with single HLA antigen are used. Beads are coated with a HLA phenotype. In addition to differences in the actual composition and nature of proteins present in micro particles, the microparticles are individually different for different machines. However, poor standardization is observed in these tests and therefore cut-off MFI value has been found to be very different between centers performing the same test. Anti-HLA class I and anti-HLA class II control antibodies are chimeric human IgG monoclonal antibodies, which are validated to recognize all class I or class II HLA antigens. In histocompatibility laboratories, the quantification of anti-HLA antibodies using solid phase techniques such as Luminex assays faces the problem of subjective cut-off values that do not take into account run-to-run and bead-to-bead variations. Standardization using commercially available anti-HLA control antibodies allows accurate interpretation of median fluorescence intensity (MFI) values in Luminex assays (laser-based techniques). This is useful for patient follow-up and identification of weak antibodies from highly sensitized patients waiting for organ transplantation. Solid phase antibody screening: DSA screening is done by using donor lysate (Life-codes, Immucor). This detects donorspecific anti-HLA class I and class II antibodies but fails to give their HLA specificities. The mixture of the beads conjugated with monoclonal antibodies helps in identification of HLA class I and class II alleles. Control beads in the mixture of beads identify the background in the assay and also ensure that appropriate conjugate is used in the test. The bead is mixed with donor lysate and then with recipient serum to identify the DSA targets for antibodies in the recipient serum.
Single antigen (SA) or multi-antigen bead assay: The solid phase assays like (single antigen bead assay) SAB. In single antigen bead assay or multi-antigen bead assay, the main advantage is increased sensitivity and specificity of the results. In SAB assay, each bead detects antibody directed against a single HLA antigen. MFI values of SAB assay quantify the intensity of each anti-HLA antibody present and help in detecting significant DSAs in recipient. Each microparticle is coated with a single HLA molecule utilizing recombinant technology. Multiplex bead antibody assay systems for anti-HLA antibodies use a solid phase platform. Panel contains all of the most frequently observed HLA alleles (97 class I and 91 class II alleles). Assay beads are mixed with recipient serum and then labeled with PE conjugated goat anti-human IgG. This assay reaction is compared with lot-specific worksheet defining the SA or multi-antigen bead assay. Panel reactive antibody (PRA) screening: Assay beads are mixed with recipient serum and then labeled with phycoerythrin (PE) conjugated with goat anti-human IgG antibody. The signal intensity of each bead is compared with negative control to identify for negative or positive reaction in the assay. PRA measurement is an indicator of broad sensitization and immune reactivity of a recipient. DSA is more specific in detecting sensitization against a particular donor. Antibodies are most commonly directed against HLA/MHC class I and II antigens. HLA class I antigens are expressed on all nucleated cells, whereas HLA class II antigens are restricted to APC (B lymphocytes, dendritic cells) and endothelial cells. Post-transplant, donor-specific HLA antibodies contribute to acute humoral (antibody-mediated) rejection characterized by rapid graft dysfunction, accompanied by the presence of circulating anti-donor HLA antibodies.
HLA antibody screening and identification has traditionally been done by cell-based techniques such as the CDC assay or by cell-based flow cytometric assays. Now, most HLA labs can test antibody by the solid phase Luminex bead-based assays. The advantages of SAB assays are the sensitivity and specificity of the results obtained. When using single antigen bead assays, for each antibody detected, a mean fluorescence intensity (MFI) value is obtained which provides a measure of the strength of each antibody. Solid phase assays by Luminex for the desensitization protocols help in identification of specificities of donor-specific anti-HLA antibody. HLA antibody testing by the solid phase Luminex bead-based assays is important for success in achieving desensitization in HLAantibody incompatible transplantation. Pre-transplant CDC cross-match along with pre-and post-transplant anti-HLA antibody testing are very important to reduce the renal allograft rejection.
Donor-specific anti-HLA antibody assays detect sensitization and also help in monitoring the recipient for development of donor-specific humoral response by DSA which could be associated with AMR. Post-transplant anti-HLA antibody (DSA) detection is important because recipients on immunosuppression could still develop de novo antibodies which can cause graft dysfunction and damage transplanted allograft. Single antigen bead assays have very low probability of giving false positive results. In solid phase assays, rarely disconnect can occur in specificities of the anti-HLA antibody detected. This could be due to alterations in SAB HLA molecule during bead creation by biotechnology. All assays based on microparticle-coated HLA antigen beads are not giving the same information, as the beads themselves, as well as the analytical platforms used to assess them are not equivalent. But all solid phase assays broadly correlate well with each other.
